AstraZeneca antibody therapy prevents COVID-19 in trial, company says
Fox News
AstraZeneca released Phase 3 data showing promising results for a combination antibody therapy that prevents COVID-19, possibly opening the door to an alternative option for people who may not see the full protective benefits from the currently authorized vaccines.
The combination of two long-acting antibodies is, according to the company, the first modified to potentially provide long-lasting protection with demonstrated clinical trial success. Also of note, over 75% of the trial participants had comorbidities, including some associated with reduced vaccine effectiveness. The trial, which included 5,197 participants, took place in multiple countries including the U.S. Data showed that the therapy was well tolerated and that there were no cases of severe COVID-19 or COVID-19-related death in participants who received the therapy. In the placebo arm, there were three cases of severe COVID-19 and two deaths. Overall the trial had 25 cases of symptomatic COVID-19.More Related News
American Culture Quiz: Test yourself on groundbreaking gadgets, medical marvels and Southern staples
The American Culture Quiz is a weekly test of our unique national traits, trends, history and people. This time, test your knowledge of groundbreaking gadgets, medical marvels and more.